Pfizer Switzerland is active at all parts of the spectrum, from vaccines that prevent diseases, to the prevention of further complications once disease strikes. The affiliate was one of the first to launch Xeljanz (tofacitinib), as a treatment in adult patients with moderate to severe active rheumatoid arthritis, building upon Pfizer’s tradition of developing patient-centered therapies. Today it is helping other European affiliates as they look to launch the product. The availability of Xeljanz provides physicians with a novel treatment option for people with rheumatoid arthritis, who previously had an inadequate response or intolerance to methotrexate, or who may prefer an oral treatment, offering an important treatment option for the Swiss RA patient.
Pfizer Switzerland plays an important role in supporting research in Switzerland. 2016 marks 25 years of the Pfizer Research Prize, celebrating young researchers. Over the last 25 years it has honored over 280 young researchers. Pfizer Switzerland also runs foundations that support both pediatric research and geriatric patients. Pfizer also works with SAKK (Swiss Group for Clinical Cancer Research), jointly awarding an honor toward patient-oriented practice relevant to research in clinical oncology.
Contact:
Schärenmoosstrasse 99
Postfach
8052 Zürich
Tel: +41 (0) 43 495 71 11
Fax: +41 (0) 43 495 72 80
Mail: info.ch@pfizer.com
Pfizer Switzerland’s Sabine Bruckner discusses Switzerland’s historic and continuing importance to Pfizer, vaccine development and uptake, and the significant benefits of building a diverse leadership team. There are challenges…
Jeff Dufour, country manager Switzerland and BU lead Internal Medicine at Pfizer, discusses his first impressions of the country, his priorities for greater dialogue with Swiss healthcare insurers, and Switzerland’s…
Pfizer Switzerland’s Pamela Alexa discusses launching Xeljanz (tofacitinib), a treatment for adult patients with moderate to severe active rheumatoid arthritis, building upon Pfizer’s tradition of developing patient-centered therapies. She also…
After seven years at the helm of the pharma industry’s biggest global trade group, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Thomas Cueni is retiring. Having played a…
Gavi, the world’s largest vaccine-focused public-private partnership has a new leader. Pakistani Senator Dr Sania Nishtar has officially assumed the role of CEO following a period of leadership uncertainty for…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
Every year, the world’s top business and political leaders converge on the ski village of Davos, Switzerland for the World Economic Forum meeting. Read on for some of the key…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
Ahead of the 78th session of the United Nations General Assembly (UNGA78), IFPMA Director General Thomas Cueni underscores the need for pandemic preparedness plans to support innovation and equity. Global…
Regular contributor Brendan Shaw* casts his eye over the recently announced 2023 WHO Essential Medicines List, how it reflects growing pharmaceutical innovation, and why maintaining a ‘seat at the table’…
Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
Brendan Shaw examines the protracted efforts of global stakeholders to come together around a global pandemic treaty and outlines the benefits of constructive engagement on the part of the pharmaceutical…
See our Cookie Privacy Policy Here
